PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.53%
Revenue growth of 2.53% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
4.70%
Positive gross profit growth while Medical - Pharmaceuticals median is negative. Peter Lynch would see a notable competitive edge in cost or pricing.
33.61%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 3.61%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
19.88%
Operating income growth of 19.88% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
11.98%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
11.99%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.12%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
11.99%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 0.12%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.20%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.19%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.19%
10Y revenue/share CAGR near Medical - Pharmaceuticals median of 39.68%. Charlie Munger might expect stable industry trends guiding long-term growth.
49.64%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 28.43%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
23.37%
3Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 15.98%. Mohnish Pabrai would attribute it to strong near-term market positioning.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.11%
Net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would confirm that management’s capital allocation strategy drives the outperformance.
35.31%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 15.30%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
27.80%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.03%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
180.29%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 53.67% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
118.59%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 30.89%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
55.15%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 16.62%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.00%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-0.48%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
0.68%
Asset growth exceeding 1.5x Medical - Pharmaceuticals median of 0.39%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
2.68%
BV/share growth of 2.68% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-50.19%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Our SG&A slightly up while Medical - Pharmaceuticals is cutting. Peter Lynch wonders if we overspend or if the median underinvests in marketing.